Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility-Reference-Cited by-同舟云学术

Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility

Published:2020-05-30 Issue:9 Volume:237 Page:2695-2707
ISSN:0033-3158
Container-title:Psychopharmacology
language:en
Short-container-title:Psychopharmacology

Author:

Byers Spencer,Buchler Ingrid P.,DePasquale Michael,Rowley Helen L.,Kulkarni Rajiv S.,Pinder Lucy,Kolobova Anna,Li Cailian,Au Vinh,Akuma Daniel,Zhang Gongliang,Wei Huijun,Cheetham Sharon C.,Barrow James C.,Carr Gregory V.^ORCID

Funder

National Institute of Mental Health

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s00213-020-05566-0.pdf

Reference60 articles.

1. Acquas E, Carboni E, de Ree RH, Da Prada M, Di Chiara G (1992) Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592. J Neurochem 59:326–330

2. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, Alce G, Iudicello JE, Akbar N, Egan MF, Goldberg TE, Weinberger DR (2007) Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 32:1011–1020

3. Apud JA, Weinberger DR (2007) Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors. CNS Drugs 21:535–557